GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4435)

  • GC81497 structure
    GC81497Vadalentamig
    CAS: 3030203-93-8
    Purity: >95.00%

    Vadalentamig is a human-derived bispecific antibody targeting NKG2D/CD314 & ERBB1/EGFR/HER1 [1] .

  • GC81499 structure
    GC81499CT-179
    CAS: 1996636-69-1
    Purity: >99.50%

    CT-179 is a brain-penetrant and orally active OLIG2 inhibitor with a human IC 50 of 1250 nM.

  • GC81512 structure
    GC81512dCDK9-202
    Purity: >98.50%

    dCDK9-202 is a CDK9 PROTAC degrader with a DC 50 of 3.5 nM.

  • GC81515 structure
    GC81515BMS-986482
    CAS: 3062993-48-7
    Purity: >98%

    BMS-986482 is a CRBN -mediated IKZF1-4 ( Ikaros family zinc finger 1-4 ) molecular glue degrader.

  • GC81516 structure
    GC81516BMS-986482 acetate
    Purity: >98.00%

    BMS-986482 acetate is a CRBN -mediated IKZF1-4 ( Ikaros family zinc finger 1-4 ) molecular glue degrader.

  • GC81517 structure
    GC81517(Rac)-BMS-986449
    Purity: >99.00%

    (R)-BMS-986449 is the racemic mixture of BMS-986449.

  • GC81519 structure
    GC81519SHP1-IN-2
    Purity: >97.00%

    SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor.

  • GC81520 structure
    GC81520Cinflumide
    CAS: 64379-93-7
    Purity: >99.50%

    Cinflumide is an orally active muscle relaxant.

  • GC81522 structure
    GC81522WWZ-11-098
    Purity: >98.00%

    WWZ-11-098 is a selective CDK6 PROTAC degrader with DC 50 of 2.6 nM.

  • GC81530 structure
    GC81530Elfetabart drozuntecan
    CAS: 3061153-84-9
    Purity: >98%

    Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate ( ADC ) targeting B7H3.

  • GC81532 structure
    GC81532Auristatin S TFA
    Purity: >99.00%

    Auristatin S TFA is a potent Auristatin payload.

  • GC81537 structure
    GC81537Risvutatug rezetecan
    CAS: 3042849-33-9
    Purity: >99.50%

    Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3 -targeting antibody-drug conjugate ( ADC ).

  • GC81540 structure
    GC81540Brevicidine TFA
    Purity: >97.50%

    Brevicidine TFA is an antimicrobial peptide with selective bactericidal activity against Gram-negative pathogens.

  • GC81541 structure
    GC81541BMAP-27 acetate
    Purity: >98.00%

    BMAP-27 acetate is a cationic amphipathic α-helical antimicrobial peptide with anticancer activity.

  • GC81542 structure
    GC815427-O-Galloyl-D-sedoheptulose
    CAS: 233690-85-2
    Purity: >98%

    7-O-Galloyl-D-sedoheptulose is an orally effective polyphenolic compound.

  • GC81543 structure
    GC81543GPX4-IN-19
    CAS: 3102894-57-2
    Purity: >99.00%

    GPX4-IN-19 is an effective GPX4 inhibitor ( IC 50 = 0.311 μM), covalently binds to the Sec 46 site of GPX4.

  • GC81544 structure
    GC81544Copper ionophore I
    CAS: 101264-90-8
    Purity: >98.00%

    Copper ionophore I is an efficient copper ion carrier.

  • GC81545 structure
    GC81545Ferroptosis inducer-12
    Purity: >96.00%

    Ferroptosis inducer-12 is a potent and selective ferroptosis inducer.

  • GC81546 structure
    GC81546iMQT_020
    CAS: 2463893-46-9
    Purity: >99.00%

    iMQT_020 is a selective allosteric SLC1A5_var inhibitor.

  • GC81547 structure
    GC81547Geranyl isovalerate
    CAS: 109-20-6
    Purity: >96.50%

    Geranyl isovalerate is a chemical component that can be extracted from Argyreia Nervosa.

  • GC81548 structure
    GC81548CIGB-552 TFA
    Purity: >98.00%

    CIGB-552 TFA is a cell-penetrating peptide with anti-tumor properties with the IC 50 of 23 μM in H460 cells.

  • GC81549 structure
    GC8154914-3-3-IN-2
    CAS: 919751-10-3
    Purity: >98.00%

    14-3-3-IN-2 is a 14-3-3 protein inhibitor with an IC 50 of 15 nM.

  • GC81551 structure
    GC81551ZNF281-IN-1
    Purity: >98%

    ZNF281-IN-1 is a ZNF281 inhibitor.

  • GC81553 structure
    GC81553YRDC-IN-1
    CAS: 3120494-74-5
    Purity: >93.50%

    YRDC-IN-1 is a blood-brain barrier-permeable YRDC inhibitor.